Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: Only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 911-919

  Kristensen, Ida B ^a,b   Christensen, Jacob Haaber ^a   Lyng, Maria B ^b   Møller, Michael B ^a   Pedersen, Lise ^a   Rasmussen, Lars M ^a,b   Ditzel, Henrik J ^a,b   Abildgaard, Niels ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Bone disease; Microenvironment; Multiple myeloma; Osteoblast; Osteoclast

Indexed keywords

DICKKOPF 1 PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN INHIBITOR; PROTEIN SFRP3; SCLEROSTIN; TELOPEPTIDE OF COLLAGEN TYPE 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; DKK1 PROTEIN, HUMAN; FRZB PROTEIN; GLYCOPROTEIN; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE MARROW BIOPSY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; BIOLOGY; BONE MARROW; CANCER STAGING; COMPLICATION; ETIOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR MICROENVIRONMENT;

ADULT; AGED; BONE MARROW; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS; TUMOR MICROENVIRONMENT;

EID: 84904324925     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.820288     Document Type: Article

References (38)

1. Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989;7:1909-1914. (Pubitemid 20014340)
2. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19-39. (Pubitemid 39335880)
3. Haaber J, Abildgaard N, Knudsen LM, et al. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 2008;140:25-35. (Pubitemid 350233249)
4. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-2494. (Pubitemid 38010074)
5. Giuliani N, Morandi F, Tagliaferri S, et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007;67:7665-7674. (Pubitemid 47281359)
6. Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.Blood 2005; 106: 3160-3165. (Pubitemid 41565914)
7. Kristensen IB, Haaber J, Lyng MB, et al. Myeloma plasma cell expression of osteoblast regulatory genes: overexpression of SFRP3 correlates with clinical bone involvement at diagnosis. Leuk Lymphoma 2013; 54: 425-427.
8. Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.Int J Cancer 2012; 131: 1466-1471.
9. Cho SW, Yang JY, Sun HJ, et al. Wnt inhibitory factor (WIF)-1 inhibits osteoblastic differentiation in mouse embryonic mesenchymal cells. Bone 2009; 44: 1069-1077.
10. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001; 98: 11581-11586. (Pubitemid 32928771)
11. Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004; 32: 685-691. (Pubitemid 39092730)
12. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-1571.
13. Kawano Y, Ueno S, Abe M, et al. TRAIL produced from multiple myeloma cells is associated with osteolytic markers. Oncol Rep 2012;27:39-44.
14. Roodman GD, Choi SJ. MIP-1 alpha and myeloma bone disease. Cancer Treat Res 2004;118:83-100.
15. Terpos E, Politou M, Szydlo R, et al. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003; 123: 106-109. (Pubitemid 37222765)
16. Terpos E, Dimopoulos MA, Sezer O, et al. The use ofbiochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010;24:1700-1712.
17. Kristensen IB, Christensen JH, Lyng MB, et al. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Br J Haematol 2013; 161: 373-382.
18. De VJ, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001;98:771-780.
19. Moreaux J, Klein B, Bataille R, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011; 96: 574-582.
20. Qiang YW, Endo Y, Rubin JS, et al. Wnt signaling in B-cell neoplasia. Oncogene 2003; 22: 1536-1545. (Pubitemid 36390603)
21. Ling L, Nurcombe V, Cool SM.Wnt signaling controls the fate of mesenchymal stem cells. Gene 2009; 433: 1-7.
22. Chung YS, Baylink DJ, Srivastava AK, et al. Effects of secreted frizzled-related protein 3 on osteoblasts in vitro. J Bone Miner Res 2004;19:1395-1402. (Pubitemid 41094340)
23. Essex SJ, Seetharam A, Barkhuizen A et al. Stable epigenetic reprogramming of bone marrow mesechymal stromal cells is seen in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2013;13(Suppl.):S37 [abstract].
24. Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion.Blood Cancer J 2011; 1: e27.
25. Standal T, Abildgaard N, Fagerli UM, et al. HGF inhibits BMP- induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007;109:3024-3030. (Pubitemid 46482103)
26. Karner E, Unger C, Cerny R, et al. Differentiation of human embryonic stem cells into osteogenic or hematopoietic lineages: a dose-dependent effect of osterix over-expression. J Cell Physiol 2009; 218: 323-333.
27. Colla S, Morandi F, Lazzaretti M, et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 2005; 19: 2166-2176. (Pubitemid 41741611)
28. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991;88: 62-66.
29. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-3533.
30. Lai FP, Cole-Sinclair M, Cheng WJ, et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 2004;126:192-201. (Pubitemid 38961937)
31. Roux S, Meignin V, Quillard J, et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 2002; 117: 86-92. (Pubitemid 34304425)
32. Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008;112:196-207.
33. Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98: 2269-2271.
34. Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002; 100: 3002-3007.
35. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100: 2195-2202. (Pubitemid 35001256)
36. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96: 671-675. (Pubitemid 30463390)
37. RoussouM, TasidouA, DimopoulosMA, et al. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 2009; 23: 2177-2181.
38. Uneda S, Hata H, Matsuno F, et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003; 120: 53-55. (Pubitemid 36056908)